SAN DIEGO , Nov. 2, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
-- Despite the impact from natural disasters and fewer sales days, revenues were up 6% and 111% in 3Q 2017 and year to date, respectively, versus the prior-year periods inclusive of the impact of conversion to accrual-based revenue recognition-- Distribution agreement signed with VWR to distribute Biocept's patented blood collection tube-- Co-Marketing agreement signed with Miraca Life Sciences-- Pathology Program initiative underway to expand adoption of Biocept's Target Selector™ platform to more community pathologists, oncologists and hematologists-- Newly launched liquid biopsy tests complete the complement of biomarker testing for breast cancer, metastatic melanoma and colorectal cancer under NCCN® Guidelines and bring the total number of commercially available liquid biopsy tests to 15-- Company to host conference call at 4:30 p.m. Eastern time today
Clinical validation of Biocept's novel PD-L1 test using multiple antibody clones has potential to improve detection, treatment selection, and patient monitoring with cancer immunotherapy
Expands Biocept's intellectual property portfolio to 21 issued patents for its highly sensitive methods of detecting cancer biomarkers on circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA)
SAN DIEGO , Dec. 6, 2017 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced that it has
Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota SAN DIEGO (December 18, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
Expands intellectual property position to 22 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)
SAN DIEGO , Jan. 26, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces
Published medical guidelines influence treatment practices and can drive clinical adoption of emerging technologies designed to improve the treatment of serious or life-threatening diseases SAN DIEGO , Jan. 30, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
